- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Impulse control disorder.
Displaying page 1 of 2.
EudraCT Number: 2007-005716-64 | Sponsor Protocol Number: 112233020781 | Start Date*: 2008-08-28 |
Sponsor Name:Universitätsklinik für Psychiatrie des Kindes- und Jugendalters, AKH Wien, Medizinische Universität | ||
Full Title: Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD... | ||
Medical condition: schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders of impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-). | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004009-93 | Sponsor Protocol Number: 12118A | Start Date*: 2008-05-20 | |||||||||||
Sponsor Name:LUNDBECK ITALIA | |||||||||||||
Full Title: Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram | |||||||||||||
Medical condition: Depression, anxiety and ICD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005839-91 | Sponsor Protocol Number: IMPULPARK | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:ASOCIACIÓN INSTITUTO BIODONOSTIA | |||||||||||||
Full Title: Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. | |||||||||||||
Medical condition: PARKINSON´S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001229-15 | Sponsor Protocol Number: 6398 | Start Date*: 2019-04-16 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
Full Title: Study of pimavanserin efficacy for the treatment of impulse control disorders in Parkinson's disease | ||
Medical condition: Impulse control disorders (ICD) in Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005538-59 | Sponsor Protocol Number: 22-09-2008 | Start Date*: 2009-02-18 |
Sponsor Name:ZonMw | ||
Full Title: Impulsivity, a risk factor in relapse to substance use disorder: investigating neural substrates before and after pharmacological challenges | ||
Medical condition: Alcohol dependence Cocaine dependence | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001338-32 | Sponsor Protocol Number: NFPA12 | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:St. Olavs Hospital Trondheim University Hospital | |||||||||||||
Full Title: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) - a randomized controlled trial. The efficacy of cabergoline on tumour volume in previously untreated macroadenomas or resid... | |||||||||||||
Medical condition: non-functioning pituitary adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005734-20 | Sponsor Protocol Number: R076477-SCA-3002 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Janssen L.P. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020956-69 | Sponsor Protocol Number: OX02 | Start Date*: 2011-02-23 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung | ||||||||||||||||||
Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001337-40 | Sponsor Protocol Number: BXCL501-105 | Start Date*: 2021-10-05 | |||||||||||||||||||||
Sponsor Name:BioXcel Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | |||||||||||||||||||||||
Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013702-14 | Sponsor Protocol Number: BETNV009 | Start Date*: 2010-08-13 | ||||||||||||||||
Sponsor Name:Hospital of the University of Munich | ||||||||||||||||||
Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial | ||||||||||||||||||
Medical condition: vestibular failure (vestibular neuritis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011824-79 | Sponsor Protocol Number: 91686125 | Start Date*: 2009-11-03 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Effects of fluoxetine on the outgrowth of the serotonergic system | |||||||||||||
Medical condition: We investigate whether the effects fluoxetine (Prozac®) on the outgrowth of the serotonergic system are dependent on age. In a 16 week multicenter randomized, double-blind, placebo controlled trial... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017271-17 | Sponsor Protocol Number: R092670-SCA-3004 | Start Date*: 2010-10-29 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004752-16 | Sponsor Protocol Number: BP40283 | Start Date*: 2021-07-30 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS | ||||||||||||||||||
Medical condition: Schizophrenia or schizoaffective disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005585-40 | Sponsor Protocol Number: A7501021 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis. | |||||||||||||
Medical condition: Acute and maintenance treatment of schizophrenia and manic episodes associated with bipolar I disorder. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003449-17 | Sponsor Protocol Number: MC/PR/15009/001/11 | Start Date*: 2012-05-31 | |||||||||||
Sponsor Name:CHIESI | |||||||||||||
Full Title: A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster NEXThaler (beclomethasone dipropionate 100 µg plus formotero... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001093-17 | Sponsor Protocol Number: 2015RC04 | Start Date*: 2016-04-22 | ||||||||||||||||
Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside | ||||||||||||||||||
Full Title: Proof of concept study to assess downstream effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on asthmatic inflammation in patients with persistent asthma and ... | ||||||||||||||||||
Medical condition: Asthma and allergic rhinitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002803-81 | Sponsor Protocol Number: TREX | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |||||||||||||
Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000060-42 | Sponsor Protocol Number: D1001066 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000061-23 | Sponsor Protocol Number: D1001067 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004878-42 | Sponsor Protocol Number: MIN-101C03 | Start Date*: 2015-02-25 | |||||||||||
Sponsor Name:Minerva Neurosciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schiz... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) RO (Suspended by CA) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
